Saturday 17 October 2026
Export ZVSA’s income statement to Excel — free account
ZyVersa Therapeutics, Inc.
ZVSA Healthcare Biotechnology
In the quarter to March 2026, EPS grew 69.9% and free cash flow grew 54.9%, each against the same quarter a year earlier.
0.05
0.00
0.00%
Follow ZVSA
ZyVersa Therapeutics, Inc. (ZVSA) P/E ratio
ZyVersa Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (July 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
88
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CRIS Curis, Inc. compare | n/m |
| BBLG Bone Biologics Corp. compare | n/m |
| ZVSA ZyVersa Therapeutics, Inc. | n/m |
| CYTOF Altamira Therapeutics Ltd. compare | n/m |
| SPRC SciSparc Ltd. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| LYRA Lyra Therapeutics, Inc. compare | n/m |
| MNTRQ 9 Meters Biopharma, Inc. compare | n/m |
| BTTX Better Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)